Skip to main content
Presentations

Approach to thrombocytopenia

The same eight steps, every presentation: threats first, then the history and exam that discriminate, one honest sentence, a mechanism-grouped differential, and the tests read in order.

  1. Immediate threats

    • Thrombotic thrombocytopenic purpura: fragments on the film with thrombocytopenia is plasma exchange tonight
    • Heparin-induced thrombocytopenia: a platelet fall 5 to 10 days into heparin with new thrombosis
    • Disseminated intravascular coagulation in a sick patient: bleeding and clotting at once
    • Intracranial or mucosal bleeding at any count; counts under 10 to 20 without bleeding still change the plan
  2. History that discriminates

    • Bleeding: bruises, petechiae, gums, nose, menorrhagia, melena; its tempo
    • Drugs, especially heparin, and the timing of every new one; alcohol; recent viral illness or vaccination
    • Pregnancy; liver disease; autoimmune disease; HIV and hepatitis C risk
    • Fever, confusion, renal symptoms (the microangiopathy pentad, rarely complete)
    • Family history and previous counts: a lifelong mild thrombocytopenia is a different problem
  3. Examination

    • Petechiae and purpura, wet purpura in the mouth (a marker of bleeding risk), fundal hemorrhage
    • Lymphadenopathy, hepatosplenomegaly, stigmata of liver disease
    • Signs of thrombosis in a patient on heparin
    • Fever and perfusion in the sick patient; neurological examination in the microangiopathy question
  4. Problem representation

    An isolated, severe thrombocytopenia in a well young woman with a normal film (immune thrombocytopenia) versus a falling count on day 7 of heparin with a new deep vein thrombosis (heparin-induced) versus fragments, anemia and a rising creatinine in a febrile confused patient (thrombotic microangiopathy).
  5. Differential, by mechanism

    Decreased production

    • Marrow failure, infiltration, myelodysplasia
    • B12 and folate deficiency
    • Alcohol
    • Chemotherapy and other drugs
    • Viral infection

    Increased destruction

    • Immune thrombocytopenia
    • Drug-induced, including heparin
    • Thrombotic microangiopathies
    • Disseminated intravascular coagulation
    • Antiphospholipid syndrome and lupus

    Sequestration and dilution

    • Hypersplenism, portal hypertension
    • Massive transfusion
    • Pregnancy (gestational thrombocytopenia, preeclampsia, HELLP)

    Artefact

    • EDTA-dependent clumping: a citrate tube and the film settle it
  6. Investigations

    • Repeat the count and look at the film before anything else: clumps, fragments, giant platelets, blasts
    • Coagulation screen with fibrinogen and D-dimer when disseminated intravascular coagulation is possible
    • Hemolysis markers and creatinine when fragments appear; a pregnancy test where relevant
    • Liver panel and an ultrasound of the spleen; B12 and folate; HIV and hepatitis C; the antibody tests for heparin-induced thrombocytopenia when the score says so
    • A marrow when a second line is down, when the film is abnormal, or when the picture is unexplained in an older patient
  7. Interpretation

    • Fragments plus thrombocytopenia is a microangiopathy; the ADAMTS13 result comes later and treatment cannot wait for it
    • The 4T score turns a suspicion of heparin-induced thrombocytopenia into a decision about stopping the heparin now
    • Immune thrombocytopenia is a diagnosis of exclusion: isolated, normal film, nothing else
    • Platelet count and bleeding risk correlate poorly; the wet purpura and the mechanism matter more than the number
  8. Next steps

    • Stop the suspect drug, above all heparin, on suspicion
    • Platelet transfusion is for bleeding and procedures, and is avoided in microangiopathy and heparin-induced disease
    • Name the mechanism: production, destruction, sequestration, dilution, artefact

Connected

Take it further

Copy this page as study notes, then paste them into QSpace for practice questions or AnkiGen for flashcards.

Open QSpace Open AnkiGen